Mariaelena Capone

4.3k total citations · 1 hit paper
68 papers, 2.2k citations indexed

About

Mariaelena Capone is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Mariaelena Capone has authored 68 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 38 papers in Molecular Biology and 33 papers in Immunology. Recurrent topics in Mariaelena Capone's work include Cancer Immunotherapy and Biomarkers (32 papers), Melanoma and MAPK Pathways (24 papers) and Immunotherapy and Immune Responses (22 papers). Mariaelena Capone is often cited by papers focused on Cancer Immunotherapy and Biomarkers (32 papers), Melanoma and MAPK Pathways (24 papers) and Immunotherapy and Immune Responses (22 papers). Mariaelena Capone collaborates with scholars based in Italy, United States and Malaysia. Mariaelena Capone's co-authors include Paolo A. Ascierto, Gabriele Madonna, Giuseppe Palmieri, Corrado Caracò, Domenico Mallardo, Antonio Maria Grimaldi, Gerardo Botti, Ester Simeone, Diana Giannarelli and Nicola Mozzillo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Biomaterials.

In The Last Decade

Mariaelena Capone

64 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

2018 351 citations Mariaelena Capone, Diana Giannarelli et al. Journal for ImmunoTherapy of Cancer profile →

Peers

Countries citing papers authored by Mariaelena Capone

Since Specialization

Citations

This map shows the geographic impact of Mariaelena Capone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mariaelena Capone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mariaelena Capone more than expected).

Fields of papers citing papers by Mariaelena Capone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mariaelena Capone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mariaelena Capone. The network helps show where Mariaelena Capone may publish in the future.

Co-authorship network of co-authors of Mariaelena Capone

This figure shows the co-authorship network connecting the top 25 collaborators of Mariaelena Capone. A scholar is included among the top collaborators of Mariaelena Capone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mariaelena Capone. Mariaelena Capone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Methylation‑sensitive restriction enzyme‑droplet digital PCR assay for the one‑step highly sensitive analysis of DNA methylation hotspots 2024 ·International Journal of Molecular Medicine ·Giuseppe Gattuso, Alessandro Lavoro, Rosario Caltabiano, Gabriele Madonna, Mariaelena Capone, Paolo A. Ascierto, Luca Falzone, Massimo Libra, Saverio Candido	11
2	Impact of sex on immune-related adverse events in patients with melanoma. 2024 ·Journal of Clinical Oncology ·Margaret Ottaviano, Domenico Mallardo, Maria Grazia Vitale, (unknown), (unknown), (unknown), Claudia Trojaniello, Francesca Sparano, (unknown), (unknown), (unknown), Ernesta Cavalcanti, Mariaelena Capone, Gabriele Madonna, Miriam Paone, Paolo Chiodini, Corrado Caracò, Ester Simeone, Paolo A. Ascierto	0
3	The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors 2024 ·Cell Death and Disease ·Domenico Liguoro, (unknown), (unknown), Andrea Sacconi, Mario Acunzo, Giulia Romano, Giovanni Nigita, Barbara Bellei, Gabriele Madonna, Mariaelena Capone, Paolo A. Ascierto, Rita Mancini, Gennaro Ciliberto, Luigi Fattore	5
4	ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma 2024 ·International Journal of Molecular Sciences ·Domenico Mallardo, (unknown), Margaret Ottaviano, (unknown), Maria Grazia Vitale, (unknown), (unknown), (unknown), Mariaelena Capone, (unknown), Miriam Paone, Patrizia Sabatelli, Rosaria De Filippi, Alessandra Cesano, Ernesta Cavalcanti, (unknown), Sarah H. Warren, Alfredo Budillon, Ester Simeone, Paolo A. Ascierto	1
5	Identification of SLC22A17 DNA methylation hotspot as a potential biomarker in cutaneous melanoma 2024 ·Journal of Translational Medicine ·Alessandro Lavoro, Luca Falzone, Giuseppe Gattuso, G. Conti, Rosario Caltabiano, Gabriele Madonna, Mariaelena Capone, James A. McCubrey, (unknown), Massimo Libra, Saverio Candido	2
6	Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition 2023 ·European Journal of Cancer ·Robert Ferguson, (unknown), (unknown), Danny Simpson, (unknown), (unknown), (unknown), Gabriele Madonna, Mariaelena Capone, Ester Simeone, Anna C. Pavlick, Jason J. Luke, Thomas F. Gajewski, Iman Osman, Paolo A. Ascierto, Jeffrey S. Weber, Tomas Kirchhoff	6
7	Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients 2023 ·Journal of Translational Medicine ·Domenico Galati, Serena Zanotta, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, (unknown), Ester Simeone, Lucia Festino, Francesca Sparano, Rosa Azzaro, Rosaria De Filippi, Antonio Pinto, Chrystal M. Paulos, Paolo A. Ascierto	8
8	Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics 2023 ·The Oncologist ·Sara Socorro Faria, Diana Giannarelli, Vladmir Cláudio Cordeiro de Lima, (unknown), Chiara Casadei, Ugo De Giorgi, Gabriele Madonna, Paolo A. Ascierto, Rossana Veronica Mendoza López, Roger Chammas, Mariaelena Capone	7
9	New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer 2023 ·International Journal of Molecular Sciences ·Susan Costantini, Gabriele Madonna, Elena Di Gennaro, Francesca Capone, (unknown), Mariaelena Capone, (unknown), (unknown), (unknown), Giuseppe Fiorentino, Roberto Parrella, Vincenzo Montesarchio, Luigi Atripaldi, Paolo A. Ascierto, Alfredo Budillon	6
10	Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma 2021 ·International Journal of Molecular Sciences ·(unknown), Antonella Iuliano, (unknown), (unknown), (unknown), (unknown), Rossella De Cegli, Sabrina Carrella, Massimiliano Salati, Annapina Russo, Giulia Russo, (unknown), Davide Cacchiarelli, Mariaelena Capone, Gabriele Madonna, Paolo A. Ascierto, Brunella Franco, Alessia Indrieri, Pietro Carotenuto	24
11	Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy 2021 ·Cancers ·Gabriele Madonna, Giuseppe Masucci, Mariaelena Capone, Domenico Mallardo, Antonio Maria Grimaldi, Ester Simeone, Vito Vanella, Lucia Festino, Marco Palla, (unknown), (unknown), (unknown), Lisa Villabona, (unknown), Hanna Eriksson, (unknown), Rolf Lewensohn, Paolo A. Ascierto	7
12	The Ratio of GrzB+ − FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma 2021 ·Cancers ·Giosuè Scognamiglio, Mariaelena Capone, Francesco Sabbatino, Annabella Di Mauro, Monica Cantile, Margherita Cerrone, Gabriele Madonna, Antonio Maria Grimaldi, Domenico Mallardo, Marco Palla, (unknown), Anna Maria Anniciello, Maurizio Di Bonito, Paolo A. Ascierto, Gerardo Botti	9
13	ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin 2019 ·Cancers ·Ciro Francesco Ruggiero, Debora Malpicci, Luigi Fattore, Gabriele Madonna, Vito Vanella, Domenico Mallardo, Domenico Liguoro, (unknown), Mariaelena Capone, Barbara Bedogni, Paolo A. Ascierto, Rita Mancini, Gennaro Ciliberto	22
14	Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma 2019 ·Scientific Reports ·Nathalie Harder, Ralf Schönmeyer, Katharina Nekolla, Armin Meier, Nicolas Brieu, (unknown), Gabriele Madonna, Mariaelena Capone, Gerardo Botti, Paolo A. Ascierto, Günter Schmidt	43
15	Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab breakdown → 2018 ·Journal for ImmunoTherapy of Cancer ·Mariaelena Capone, Diana Giannarelli, Domenico Mallardo, Gabriele Madonna, Lucia Festino, Antonio Maria Grimaldi, Vito Vanella, Ester Simeone, Miriam Paone, Giuseppe Palmieri, Ernesta Cavalcanti, Corrado Caracò, Paolo A. Ascierto	351
16	A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma 2017 ·Cancer Immunology Research ·Jeffrey S. Weber, Mario Sznol, Ryan J. Sullivan, Shauna Blackmon, Genevieve M. Boland, Harriet M. Kluger, Ruth Halaban, Antonietta Bacchiocchi, Paolo A. Ascierto, Mariaelena Capone, Carlos Oliveira, Krista Meyer, Julia Grigorieva, (unknown), Joanna Roder, Heinrich Röder	53
17	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab 2017 ·OncoImmunology ·Gabriele Madonna, Carmen Ballesteros‐Merino, Zipei Feng, Carlo Bifulco, Mariaelena Capone, Diana Giannarelli, Domenico Mallardo, Ester Simeone, Antonio Maria Grimaldi, Corrado Caracò, Gerardo Botti, Bernard A. Fox, Paolo A. Ascierto	46
18	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab 2016 ·Clinical Cancer Research ·Alexander Martens, Kilian Wistuba‐Hamprecht, Jianda Yuan, Michael A. Postow, Phillip Wong, Mariaelena Capone, Gabriele Madonna, Amir Khammari, Bastian Schilling, Antje Sucker, Dirk Schadendorf, Peter Martus, Brigitte Dréno, Paolo A. Ascierto, Jedd D. Wolchok, Graham Pawelec, Claus Garbe, Benjamin Weide	141
19	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy 2015 ·OncoImmunology ·Nicola Mozzillo, Ester Simeone, (unknown), Marcello Curvietto, Diana Giannarelli, Giusy Gentilcore, Rosa Camerlingo, Mariaelena Capone, Gabriele Madonna, Lucia Festino, Corrado Caracò, Gianluca Di Monta, Ugo Marone, Massimiliano Di Marzo, Antonio Maria Grimaldi, Stefano Mori, Gennaro Ciliberto, Paolo A. Ascierto	55
20	BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma 2012 ·Journal of Clinical Oncology ·Maria Colombino, Mariaelena Capone, Amelia Lissia, Antonio Cossu, Corrado Rubino, Vincenzo De Giorgi, Daniela Massi, Ester Fonsatti, Stefania Staibano, Oscar Nappi, Elena Pagani, Milena Casula, Antonella Manca, Maria Cristina Sini, Renato Franco, Gerardo Botti, Corrado Caracò, Nicola Mozzillo, Paolo A. Ascierto, Giuseppe Palmieri	360

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact